The coronavirus vaccine produced by Oxford University and AstraZeneca, the most promising of the 30 companies currently completing clinical trials, could be available before the end of the year.
This is an optimistic sign, especially ahead of what is expected to be a tough winter.
This revelation has come from India as the Serum Institute in Pune, one of the companies that will manufacture it, has announced that it can probably be launched 73 days after the start of Phase 3 trials: this date would be November 3, 2020.
The Institute has stated that Phase 3 trials with human beings are underway.
After this, the results will go through an assessment phase and, if this is positive, the license will be granted.
The Serum Institute of India, a leading vaccine manufacturer, is partnering with Gavi – the Vaccine Alliance – and the Bill & Melinda Gates Foundation to manufacture and deliver up to 100 million doses of COVID-19 vaccines to India and developing countries.
This vaccine will be administered in a single dose and Pascal Soriot, CEO of AstraZeneca, has said that the vaccine is in fact already being produced to have millions of doses ready when it is approved and can quickly begin to be distributed.
The company is taking the financial risk that the results of the trials will not finally be as expected.
However, the Phase I and II trials have been successful.
According to statements made by AstraZeneca, the price of a dose of this vaccine will be around three euros.
There are big differences between the prices announced for the different vaccines in development: Sinopharm’s Chinese vaccine would cost 120 euros, GSK-Sanofi’s around 10 euros and Moderna’s around 30 euros.
- سيعجبك أيضاً